Dr. László B. Tankó Joins HERVolution's Advisory Board to Enhance Cardiometabolic Research

HERVolution Therapeutics Strengthens Its Team with Dr. László B. Tankó

HERVolution Therapeutics, a pioneering biotechnology company focusing on human endogenous retrovirus (HERV)-targeting immunotherapies for various health issues, has recently made a significant enhancement to its Scientific Advisory Board (SAB) by appointing Dr. László B. Tankó. With over 25 years of clinical leadership experience in the global arena, Tankó is expected to significantly contribute to the company’s cardiometabolic clinical development strategy.

Background on Dr. László B. Tankó

Dr. Tankó brings a wealth of knowledge and experience in clinical development, particularly within the fields of cardiometabolic health, musculoskeletal diseases, and oncology. His appointment comes at a critical time as HERVolution prepares to advance its lead program, IPT-001. This advanced immunotherapy targets HERV-K, an essential retroviral element linked to age-related diseases, with a focus on metabolic conditions such as pre-diabetes and type 2 diabetes.

Before joining HERVolution, Tankó served as Chief Medical Officer at SixPeaks Bio AG in Switzerland, where he spearheaded the development of an innovative anti-ActRII monoclonal antibody aimed at improving glycemic control and weight management. His leadership not only helped SixPeaks Bio achieve Investigational New Drug (IND) readiness but also culminated in a $300 million acquisition by AstraZeneca, showcasing his ability to drive impactful clinical programs from conception through regulatory hurdles to market.

The Potential of IPT-001

HERVolution's IPT-001 is touted as a first-in-class senolytic insulin sensitizer that specifically targets HERV-K-expressing senescent cells, addressing underlying biological causes of metabolic aging and related disorders. By eliciting a targeted immune response, IPT-001 aims to go beyond merely alleviating symptoms of metabolic diseases, seeking to combat root causes instead. This innovative approach signifies a substantial leap in treating age-related metabolic conditions.

As the company gears up for first-in-human trials in 2026, Dr. Tankó's expertise in clinical strategy and regulatory engagement is seen as crucial for steering IPT-001 through the complexities of clinical development and FDA/EMA approval processes.

Dr. Tankó's Previous Leadership Roles

Dr. Tankó's distinguished career has included pivotal roles at renowned organizations such as Ferring Pharmaceuticals, Novartis, and Bayer. His extensive work in women's health, obesity, metabolic syndrome, cardiovascular diseases, and more, has equipped him with a deep understanding of global clinical development, making him a highly respected figure in the scientific community. He boasts a strong publication record with over 110 peer-reviewed articles and numerous patents.

Commenting on his new role, Dr. Tankó expressed his enthusiasm: “I have meticulously followed the evolution of HERV biology as a therapeutic target and believe that HERVolution is uniquely positioned to translate these scientific insights into tangible clinical benefits for patients. I am eager to leverage my experience in clinical operations and regulatory strategy to expedite the advancement of this groundbreaking pipeline.”

Looking Ahead

HERVolution is not only focusing on oncology but also on metabolic diseases and age-related health decline through its innovative immunotherapies. With the integration of Dr. Tankó into the team, the company is poised to navigate the coming years successfully and make substantial contributions to the field of cardiometabolic health.

Headquartered in Copenhagen, Denmark, HERVolution is at the forefront of developing therapies that target HERVs, leveraging a proprietary engineering platform to create solutions that address the drivers of health-related challenges. The anticipated first-in-human studies in 2026 mark a promising step forward for the company and its ambitious mission.

For more details about HERVolution Therapeutics and its initiatives, visit HERVolutionTx.com or follow them on LinkedIn and X.